| Dr Heather A Posillico, DO | |
|
259 First Street, Emergency Department, Mineola, NY 11501 | |
| (516) 663-2211 | |
| Not Available |
| Full Name | Dr Heather A Posillico |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 259 First Street, Mineola, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003108184 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 278770-1 (New York) | Primary |
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
The New York Times explores how intra-GOP allegiances to the business community are changing. Meanwhile, AARP acknowleges that adjustments must be made, but argues against cutting back entitlements. Also in the news, the director of the National Institutes of Health expresses his wariness about the impact sequestration could have on biomedical research.
Roche announced today the commercial availability of the cobas HBVassay for use on the cobas 4800 System in countries accepting the CE mark. This new molecular diagnostic assay expands the available virology menu on the cobas 4800 System, improving system efficiency and providing testing flexibility that allows physicians to assess a patient's response to antiviral therapy.
Researchers at the University of Illinois at Chicago have shown for the first time that damage to a particular area of the brain and a consequent reduction in noradrenaline are associated with multiple sclerosis.
Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.
Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.
› Verified 5 days ago
| Entity Name | Winthrop Community Medical Affiliates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457873077 PECOS PAC ID: 5698092385 Enrollment ID: O20150317001669 |
News Archive
The New York Times explores how intra-GOP allegiances to the business community are changing. Meanwhile, AARP acknowleges that adjustments must be made, but argues against cutting back entitlements. Also in the news, the director of the National Institutes of Health expresses his wariness about the impact sequestration could have on biomedical research.
Roche announced today the commercial availability of the cobas HBVassay for use on the cobas 4800 System in countries accepting the CE mark. This new molecular diagnostic assay expands the available virology menu on the cobas 4800 System, improving system efficiency and providing testing flexibility that allows physicians to assess a patient's response to antiviral therapy.
Researchers at the University of Illinois at Chicago have shown for the first time that damage to a particular area of the brain and a consequent reduction in noradrenaline are associated with multiple sclerosis.
Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.
Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Heather A Posillico, DO 259 First Street, Emergency Department, Mineola, NY 11501 Ph: (516) 663-2211 | Dr Heather A Posillico, DO 259 First Street, Emergency Department, Mineola, NY 11501 Ph: (516) 663-2211 |
News Archive
The New York Times explores how intra-GOP allegiances to the business community are changing. Meanwhile, AARP acknowleges that adjustments must be made, but argues against cutting back entitlements. Also in the news, the director of the National Institutes of Health expresses his wariness about the impact sequestration could have on biomedical research.
Roche announced today the commercial availability of the cobas HBVassay for use on the cobas 4800 System in countries accepting the CE mark. This new molecular diagnostic assay expands the available virology menu on the cobas 4800 System, improving system efficiency and providing testing flexibility that allows physicians to assess a patient's response to antiviral therapy.
Researchers at the University of Illinois at Chicago have shown for the first time that damage to a particular area of the brain and a consequent reduction in noradrenaline are associated with multiple sclerosis.
Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.
Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.
› Verified 5 days ago
Dr. Martin S. Kohn, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 259 1st St, Mineola, NY 11501 Phone: 516-663-2727 Fax: 516-663-8549 | |
Dr. Ronald A. Paynter, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 259 1st St, Mineola, NY 11501 Phone: 516-663-2727 Fax: 516-663-8549 | |
Dr. Edward Mintz, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 259 1st St, Mineola, NY 11501 Phone: 516-663-2727 Fax: 516-663-8549 | |
Scott A. Gorenstein, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 120 Mineola Blvd, Suite 360, Mineola, NY 11501 Phone: 516-663-8498 Fax: 516-663-9765 | |
Dr. Kenneth Steinberg, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 292 Herricks Rd, Mineola, NY 11501 Phone: 516-294-8910 Fax: 516-294-4009 | |
Mrs. Jane Avella, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 292 Herricks Rd, Mineola, NY 11501 Phone: 516-294-8910 Fax: 516-294-4009 |